Coloplast A/S Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
The quarterly results for Coloplast A/S (CPH:COLO B) were released last week, making it a good time to revisit its performance. Coloplast reported kr.7.4b in revenue, roughly in line with analyst forecasts, although statutory earnings per share (EPS) of kr.6.49 beat expectations, being 6.6% higher than what the analysts expected. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
After the latest results, the 20 analysts covering Coloplast are now predicting revenues of kr.30.8b in 2027. If met, this would reflect a meaningful 8.2% improvement in revenue compared to the last 12 months. Per-share earnings are expected to soar 112% to kr.26.01. Before this earnings report, the analysts had been forecasting revenues of kr.30.8b and earnings per share (EPS) of kr.26.27 in 2027. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.
See our latest analysis for Coloplast
It will come as no surprise then, to learn that the consensus price target is largely unchanged at kr.467. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic Coloplast analyst has a price target of kr.625 per share, while the most pessimistic values it at kr.370. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Coloplast's past performance and to peers in the same industry. We can infer from the latest estimates that forecasts expect a continuation of Coloplast'shistorical trends, as the 6.5% annualised revenue growth to the end of 2027 is roughly in line with the 8.0% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 7.3% annually. So although Coloplast is expected to maintain its revenue growth rate, it's only growing at about the rate of the wider industry.
The Bottom Line
The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Coloplast going out to 2028, and you can see them free on our platform here..
Even so, be aware that Coloplast is showing 4 warning signs in our investment analysis , you should know about...
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.